Clinical Trial Update: A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain [Phase 3]

View source ↗

Summary

A phase 3 study of elagolix in endometriosis with moderate to severe pain was terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• Elagolix (elagolix)

Snippet

Sponsor: AbbVie | Conditions: Endometriosis | Phase 3 | Status: TERMINATED | Results posted: 2019-11-27